Clinical characteristics, diagnosis, and risk stratification of pulmonary hypertension in severe tricuspid regurgitation and implications for transcatheter tricuspid valve repair

Abstract Aims Patients with pulmonary hypertension (PHT) are often excluded from surgical therapies for tricuspid regurgitation (TR). Transcatheter tricuspid valve repair (TTVR) with the MitraClip™ technique is a novel treatment option for these patients. We aimed to assess the role of PHT in severe...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2020-08, Vol.41 (29), p.2785-2795
Main Authors: Lurz, Philipp, Orban, Mathias, Besler, Christian, Braun, Daniel, Schlotter, Florian, Noack, Thilo, Desch, Steffen, Karam, Nicole, Kresoja, Karl-Patrik, Hagl, Christian, Borger, Michael, Nabauer, Michael, Massberg, Steffen, Thiele, Holger, Hausleiter, Jörg, Rommel, Karl-Philipp
Format: Article
Language:English
Subjects:
Cardiac Catheterization
Heart Valve Prosthesis Implantation
Humans
Hypertension, Pulmonary
Recovery of Function
Risk Assessment
Time Factors
Treatment Outcome
Tricuspid Valve - diagnostic imaging
Tricuspid Valve - surgery
Tricuspid Valve Insufficiency - diagnostic imaging
Tricuspid Valve Insufficiency - surgery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Patients with pulmonary hypertension (PHT) are often excluded from surgical therapies for tricuspid regurgitation (TR). Transcatheter tricuspid valve repair (TTVR) with the MitraClip™ technique is a novel treatment option for these patients. We aimed to assess the role of PHT in severe TR and its implications for TTVR. Methods and results A total of 243 patients underwent TTVR at two centres. One hundred twenty-one patients were grouped as iPHT+ [invasive systolic pulmonary artery pressures (PAPs) ≥50 mmHg]. Patients were similarly stratified according to echocardiographic PAPs (ePHT). The occurrence of the combined clinical endpoint (death, heart failure hospitalization, and reintervention) was investigated during a follow-up of 330 (interquartile range 175–402) days. iPHT+ patients were at higher preoperative risk (P 
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehaa138